Jazz Pharmaceuticals

The CIN framework assigns Jazz Pharmaceuticals a Neutral rating at 58/100, with conviction of 2 out of 5. Four pillars feed the composite in fixed weights (35/25/25/15 for fundamentals, regulatory, market, and editorial), and no clause of the score is hidden from the reader. Fundamentals carries this profile, printing 88 and setting the ceiling on the composite. The editorial pillar sits at 30, and is the main drag on the composite.

Under the hood, the data points sit as follows: reported revenue growth of 19.1 percent year over year, an operating margin of 23.5 percent, gross margin of 91.5 percent, a market cap near 15.3 billion, a jurisdictional posture reading of 50. Each of those figures ties back to a specific input in the pillar breakdown. The scoring pipeline pulls only from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage, and each pillar exposes its own inputs. This lets Jazz Pharmaceuticals be lined up against the US operator peer set on identical inputs, with refresh cadence tied directly to primary-source ingest.

The forward path is set by fundamentals, which carry 88 of this rating. A quarterly print showing revenue above the trailing four-quarter run rate — paired with a defensible operating margin — would justify a tighter band; the reverse would loosen it.